Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,682 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07004647Recruiting
MT027 cell injection for advanced peritoneal tumors
This trial tests an experimental cell therapy, MT027, for people with advanced peritoneal tumors that have stopped responding to standard treatments. The goal is to see if MT027 can shrink tumors when injected directly into the abdomen.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06630806RecruitingPhase 1
Study of an injection for relapsed or refractory myeloma
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07691463Recruiting
How light-sensitive cells help your eye focus
This trial studies how different types of light-sensitive cells in your eye work to help you focus. It involves sitting still and looking at lights while measurements are taken.
Rochester, New YorkAges Up to 35 years - NCT07467122RecruitingPhase 1
TCR-T cell therapy for MAGE-A4-positive sarcomas and other tumors
This trial tests a personalized cell therapy called TCR-T that targets a protein called MAGE-A4 on tumor cells. It is for people with advanced sarcomas or similar cancers that have not responded to standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07457346RecruitingPhase 2
Testing emactinib with chemo and immunotherapy before head and neck cancer surgery
This trial tests whether combining the drug emactinib with chemotherapy and immunotherapy before surgery helps treat advanced head and neck cancer. It aims to shrink tumors and make surgery more effective.
Hangzhou, ZhejiangAges 18–75 - NCT04293042RecruitingEarly Phase 1
BK virus treatment using donor immune cells after transplant
This early-phase study tests whether immune cells made from a donor (T cells) can treat BK virus infection in people whose immune system is weak after a stem cell transplant or chemotherapy. It may help control the virus causing bladder/urinary symptoms.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT07402616Recruiting
Studying skin cancer tumors after surgery
This trial looks at skin cancer tumors removed during surgery to better understand how they grow. It may help you if you are an adult with a common type of skin cancer called squamous cell carcinoma that is not in a sensitive area and is not too large.
CopenhagenAges 18 years+ - NCT06958679RecruitingPhase 1
Study of SYS6005 for advanced solid tumors and lymphomas
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
TianjinAges 18 years+ - NCT07430579Recruiting
Adebrelimab with chemo for esophageal cancer
This trial tests adding adebrelimab (an immunotherapy drug) to standard chemotherapy for people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination helps shrink tumors before surgery.
JinanAges 18–80 - NCT05776173Recruiting
Gene-modified stem cell treatment for transfusion-dependent thalassemia
This trial tests whether giving you your own (autologous) gene-modified blood stem cells can improve transfusion-dependent beta-thalassemia and its safety. It may help people who do not have a fully matched donor and need an alternative approach to care.
ShanghaiAges 6–35 - NCT06947694RecruitingPhase 2
Testing radioimmunotherapy combinations for lung cancer with metastases
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07120633Recruiting
CAR-T cell therapy plus BTK inhibitor for high-risk CLL/SLL
This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.
Xuzhou, JiangsuAges 18 years+ - NCT06777719RecruitingPhase 1
A study of immune cells to prevent kidney rejection
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
NantesAges 18–99 - NCT07359014Recruiting
Dual-target car-t cell therapy for multiple myeloma
This trial tests a new type of immunotherapy using your own immune cells (called CAR-T cells) that are modified to attack two targets (CD19 and BCMA) on myeloma cells. It is for patients whose myeloma has come back or stopped responding to standard treatments.
HangzhouAges 18–75 - NCT06583083RecruitingPhase 2
Sintilimab plus chemo vs chemo alone for advanced ENKTL lymphoma
This trial tests whether adding the immunotherapy drug sintilimab to a standard chemotherapy regimen (P-GEMOX) works better than chemotherapy alone for people with advanced ENKTL lymphoma. The goal is to see if the combination improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07413042RecruitingPhase 1
Radiation drug combined with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
Beijing, Beijing MunicipalityAges 18–80 - NCT07611825RecruitingPhase 2
Gut Bacteria Treatment for Advanced Kidney Cancer Resistant to Immunotherapy
This study tests whether modifying your gut bacteria can help immunotherapy work again in advanced kidney cancer that has stopped responding to initial immune-checkpoint inhibitor treatment. Researchers will give you a special bacterial preparation along with a new immunotherapy drug to see if this combination can slow or shrink your cancer.
Nanjing, JiangsuAges 18–90 - NCT06576635Recruiting
Chemotherapy study for advanced lung cancer
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
Chicago, IllinoisAges 18 years+ - NCT05529342Enrolling by invitation
Long-term follow-up for a prior gene-cell treatment
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07388771Recruiting
Predicting treatment results for lung cancer before surgery
This trial is testing a treatment given before surgery for non-small cell lung cancer. Patients receive chemotherapy plus immunotherapy (chemo-immunotherapy) first, then have surgery to remove the tumor. The goal is to see how well this approach works.
Wuhan, HubeiAges 18 years+ - NCT06880380RecruitingPhase 1
CAR-T cell therapy for functional HIV cure
This trial tests whether CAR-T cells can help control HIV without daily antivirals. It is for people with well-controlled HIV who want to explore a potential functional cure.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06414889RecruitingPhase 1
Collecting stem cells safely in RUNX1 platelet disorder
This study tests the safety of collecting your own blood stem cells (called CD34+ cells) using a process called apheresis. It is for people with RUNX1 familial platelet disorder who may need a stem cell transplant in the future.
Houston, TexasAges 18–75 - NCT07374679Recruiting
Long-term safety and effectiveness of stem cells for rotator cuff disease
This study follows up with people who already received an experimental stem cell treatment for rotator cuff disease in a previous trial. It aims to check if the treatment remains safe and effective over time.
Seoul, KoreaAges 19 years+ - NCT07369596Recruiting
Chemotherapy doses and survival in older lung cancer patients
This study looks at how lowering chemotherapy doses affects survival in older patients with advanced lung cancer who do not have certain genetic mutations. It may help doctors understand the best way to treat this group.
Hong KongAges 65 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,682 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.